# Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

> **NCT06579105** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 406 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo (placebo matching AZD5004 film-coated tablet)
- **DRUG:** AZD5004
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT06579105
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-08
- **Primary completion:** 2025-12-19
- **Final completion:** 2025-12-19
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06579105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06579105, "Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06579105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*